InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million
InterCure (NASDAQ:INCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
InterCure (NASDAQ:INCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.